Crohn’s Disease

9:30 – 9:50 am

Natasha Bollegala, Hon BSc., MD, MSc., FRCP(C)

Staff Gastroenterologist, Women’s College Hospital
Assistant Professor, Faculty of Medicine, University of Toronto
Clinician In Quality & Innovation, University of Toronto

Dr. Natasha Bollegala HonBSc, MD, MSc, FRCPC is a staff gastroenterologist at Women’s College Hospital, Assistant Professor in the Department of Medicine, University of Toronto (UofT). She is a clinician in quality and innovation and completed an Inflammatory Bowel Disease (IBD) fellowship at Mount Sinai Hospital, Toronto, an MSc in clinical epidemiology and healthcare research at UofT in 2016, the Eliot Phillipson Clinician Scientist Training Program and the Clinician Investigator Program at the University of Toronto. 

Dr. Bollegala conducts research with a particular focus on pediatric to adult transition of care and is co-principle investigator for the national transition arm of the Promoting Access to Care in IBD (PACE) quality improvement program of Crohn’s and Colitis Canada (CCC).  She co-chairs the Canadian IBD Transition Network (CITE). She has published and presented on the topic of gender in gastroenterology. She is co-chair of the Innovations sub-committee for the Quality Affairs Committee of the Canadian Association of Gastroenterology (CAG). She services as executive secretary for the Ontario Association of Gastroenterology (OAG). 

Presentation Overview:
This presentation will be a condensed presentation of highlights from the DDW 2022 meeting pertaining to Crohn's Disease. 

Abstract numbers

  • 985❙deBruynJCC, et al.Comparison of One-Year Outcomes Between Adalimumab and Infliximab in Children with Luminal Crohn's Disease: A Multicenter Prospective Cohort Study
  • 885❙ColombelJ-F, et al.Triple Combination Therapy with Vedolizumab, Adalimumab, and Methotrexate in Patients with High-Risk Crohn’s Disease: Interim Analysis from the Open-Label, Phase 4 EXPLORER Trial
  • Mo1543❙BessissowT, et al.Real-World Effectiveness of Ustekinumab in Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease in Canada
  • 867f❙ColombelJ-F, et al. Efficacy and Safety of Upadacitinib Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologics: Results from aRandomized Phase 3 U-EXCEED Study